Top Midday Decliners
2:03PM ET 5/23/2022 MT NewswiresNymox Pharmaceutical (NYMX) said it received a refusal-to-file letter from the US Food and Drug Administration indicating the company needs to include...
Quotes Snapshot > ATHX
Athersys Inc ATHX:NASDAQ
Last Price$0.18NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/25/22
Today's Change-0.02(7.83%)
Bid (Size)$0.19 (452)
Ask (Size)$0.19 (33)
Day Low / High$0.18 - 0.20
Volume90.9 K
Read more news Recent News
Athersys Shares Drop After BofA Securities Downgrade
12:15PM ET 5/23/2022 MT NewswiresAthersys (ATHX) shares shed about 18% in Monday afternoon trading after BofA Securities downgraded the stock to underperform from neutral and slashed its...
--BofA Securities Downgrades Athersys to Underperform From Neutral, Adjusts Price Target to $0.25 From $1
9:08AM ET 5/23/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Athersys Shares Tumble Pre-Bell as MultiStem Study Misses Primary Endpoint
8:48AM ET 5/20/2022 MT NewswiresAthersys, Inc. (ATHX) shares are down more than 50% in premarket trading after the biotech company reported Friday that a study of its MultiStem ischemic...
View all Commentary and Analysis
Athersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking AlphaAthersys - Hero Or Zero Opportunity
10:56AM ET 4/18/2022 Seeking AlphaAthersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript
8:47PM ET 3/15/2022 Seeking AlphaAthersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
2:34PM ET 1/20/2022 Seeking AlphaCompany Profile
Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 05/12/2022 8-K |
| Chief Executive Officer & Director | Daniel A. Camardo |
| President & Chief Operating Officer | William B. J. Lehmann |
| Chief Financial & Accounting Officer | Ivor MacLeod |
| Director, Chief Scientific Officer & Executive VP | John J. Harrington |
Company Highlights
| Price Open | $0.20 |
| Previous Close | $0.18 |
| 52 Week Range | $0.18 - 1.81 |
| Market Capitalization | $46.6 M |
| Shares Outstanding | 252.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.35 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -981.52% |
| Return on Equity | -429.24% |
Analyst Ratings as of 05/20/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |